| |
Milestones
- Capsulin™ oral insulin receives world-wide
media attention and positive comments from diabetes charities
- Positive results from Capsulin™ oral insulin
phase II in type 2 diabetes presented at 67th Scientific Sessions of
the ADA
- Capsitonin™ oral calcitonin successfully completes
recruitment and dosing of 36-patient phase II study
- Bone Medical Ltd raises A$2.1M with exercise of options
- Infexion successfully develops a new immunostimulatory
presentation system for nasal or parenterally delivered vaccinations
- Recognition of calcitonin as effective therapeutic
for osteoarthritis
- Arthritis drug candidate that downregulates TNF (BN006)
undergoing advanced testing at the Kennedy Institute lead by Professor
Feldmann
- Phase II trial on oral insulin product Capsulin™
in patients with type 2 diabetes positive
- Ethics approval for phase II Axcess formulated calcitonin
(Capsitonin™) study in osteoporosis
- US freedom-to-operate review completed on Axcess
2 and 3 patent families
- First repeat dosing of Capsulin™ oral insulin
achieved in phase II study on patients with type 2 diabetes
- Positive results from preclinical study into Axcess
formulated oral GLP-1 analogues
- Bone Medical Ltd raises A$1.8M in private placement
- Successful pre-clinical study in TNF downregulator (BN006) for treatment
of rheumatoid arthritis
- Axcess 4 patent successfully filed broadening choices
for new proteins to be delivered orally
- Bone Medical Ltd enters collaboration with Synovo
on BN006 testing
- Pre-IND meeting with FDA regarding Axcess formulated insulin (Capsulin™)
for diabetes
- Positive results announced from phase I trial of
Axcess formulated oral PTH product Perthoxal™
- Pre-IND meeting with FDA regarding Axcess formulated
sCT (Capsitonin™) for osteoporosis
- Enters 'Universal Vaccine' collaboration addressing seasonal and pandemic
influenza - two year project gains €1.2 M EU grant
- Completed phase I trial of Axcess formulated oral PTH product (Perthoxal™)
- BIO-IB Inc. appointed as financial advisors to Bone Medical Ltd
- Appointment of Dr Juergen Parrisius as key executive of Proxima Laboratory
and Research Services Ltd
- Capsulin™ results received well at 65th Scientific Sessions
of the ADA
- Positive result in arthritis drug candidate that downregulates TNF
(BN006)
- Positive collagen tolerance study using RIA mouse model
- Phase IIa trial on oral insulin product Capsulin™ in type 1
diabetes positive
- Appointment of Tim Earle as Group Commercial Director
- First positive phase I/II result in man for Axcess
formulated calcitonin (Capsitonin™)
- Appointment of Dr Anthony Lockett as Medical Director
of Group and Diabetology Ltd
- Capsulin™ phase I results get positive reception
at 64th Scientific Sessions of the ADA
- First Mozaic patent granted
- Lexcicon discovery
- Discovery of new class of potential arthritis therapeutics
which downregulate TNF
- Establishment of Proxima Laboratory and Management
Services Ltd
- Commencement of Phase IIa with capsule insulin (Capsulin™)
- Bone Ltd "reverses" into ASX listed company
- now Bone Medical Ltd and raises $4.5m
- First Vaxcine patent granted
- First positive phase I result in man for Axcess formulated
insulin
- Kancer Ltd established
- Diabetology Ltd established
- Bone Ltd established
- Second MTA Agreement for development of another Axcess
formulated peptide with second Multinational
- MTA Agreement for development of an Axcess formulated
peptide with Multinational
- Acquired: Vaxcine Patents
- Established Sino/British Joint Venture near Beijing
for pre-clinical testing
- Achieved funding from the International Healthcare
Trust
- First positive preclinical tests for Axcess
- Lodged first Axcess patent
- Appointment of Gurpal Bansal as contract lab manager
- Acquired: Mozaic patents
- Proxima Concepts Ltd Established
- Roger New and Glen Travers form new entity to tackle
Major Biopharmaceutical industry challenges
|
